Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT01247415
Other study ID # pcirn-clin-invest-aller-1011
Secondary ID
Status Active, not recruiting
Phase N/A
First received November 22, 2010
Last updated July 3, 2012
Start date January 2011
Est. completion date November 2012

Study information

Verified date July 2012
Source PHAC/CIHR Influenza Research Network
Contact n/a
Is FDA regulated No
Health authority Canada: Canadian Institutes of Health ResearchCanada: Ethics Review CommitteeCanada: Health Canada
Study type Observational

Clinical Trial Summary

During the 2009-2010 immunization campaign against pandemic H1N1, some people reported having allergic-like reactions (anaphylaxis(a shock-like reaction), hives, swelling, etc.). A vaccine allergy may be more or less severe or intense. Patients may have skin reactions (rash with or without itching), respiratory problems (cough, spasm of the airways), angioedema (swelling) of various body parts (face, eyelids, throat etc.) and circulatory problems (low blood pressure or shock). Anaphylaxis is a severe allergic reaction that can sometimes be fatal. Other people vaccinated against pandemic H1N1 had an oculo-respiratory syndrome. Oculo-respiratory syndrome (ORS) is also a reaction to the influenza vaccine, which includes symptoms such as bilateral conjunctivitis (red eyes) with swelling of the face or respiratory symptoms (chest tightness, coughing, a sensation of throat closure, difficulty swallowing, hoarseness, wheezing or difficulty breathing). The investigators know that ORS is not a true allergic reaction. Because many signs and symptoms of ORS are similar to those observed during an allergic reaction, it is often difficult to distinguish ORS from an allergic reaction.

This study will compare three groups of patients: those who had allergic-like reactions, those who had ORS and vaccinated individuals who had no such adverse events. Pregnant women cannot participate in this study. The study has three goals. First, the investigators want to determine, among those who had allergic-like reactions after influenza vaccination, what proportion (percentage) of these people are actually allergic to the vaccine or its components. Second, among those who are not allergic to the vaccine, which other processes may have caused these symptoms. Finally, the investigators will try to identify whether there are features that distinguish patients who have a true allergic reaction from those affected by ORS, and those that had no adverse events.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 138
Est. completion date November 2012
Est. primary completion date March 2011
Accepts healthy volunteers No
Gender Both
Age group 10 Years to 64 Years
Eligibility case:

Inclusion Criteria:

- There will be three groups of cases. For all groups of cases, patients will be included if the time of onset of their first symptoms has been within 24 hours after vaccination and if they are between 10 and 64 years of age.

- Anaphylaxis: these patients will have to meet at least level 3 of diagnostic certainty according to the Brighton Collaboration criteria for anaphylaxis

- Allergic-like reactions: These patients will have to have displayed at least one sign or symptom of an allergic reaction (any of the minor or major criteria of anaphylaxis) but will exclude patients with conjunctivitis who will belong to the ORS group (see below).

- ORS cases: According to the Public Health Agency case definition, these patients should have presented a bilateral conjunctivitis plus =1 of the seven respiratory symptoms (cough, wheeze, chest tightness, difficulty breathing, difficulty swallowing, hoarseness or sore throat) that started within 24 hrs of vaccination, with or without facial oedema (no restriction for duration)

- Controls will be individuals between 10 and 64 years of age who received the pH1N1 vaccine but did not present any of the above mentioned adverse events after their vaccine (anaphylaxis, allergic like reactions and SOR).

Exclusion Criteria:

-Pregnant women cannot participate in this study.

Study Design

Observational Model: Case Control, Time Perspective: Retrospective


Locations

Country Name City State
Canada Centre Hospitalier Charles Lemoyne Greenfield-Park Quebec
Canada Centre Hospitalier Universitaire de Montréal Montréal Quebec
Canada Hôpitale Ste-Justine Montréal Quebec
Canada Montreal Children's Hospital Montréal Quebec
Canada Montreal General Hospital Montréal Quebec
Canada Centre Hospitalier Universitaire de Québec Québec Quebec
Canada Centre Hospitalier et Universitaire de Sherbrooke Sherbrooke Quebec

Sponsors (20)

Lead Sponsor Collaborator
PHAC/CIHR Influenza Research Network British Columbia Centre for Disease Control, Centre hospitalier de l'Université de Montréal (CHUM), Centre Hospitalier Universitaire de Québec, CHU de Québec, Centre Hospitalier Universitaire de Sherbrooke, Hopital Charles Lemoyne, Institut National en Santé Publique du Québec, IWK Health Centre, Laval University, McMaster University, Montreal Children's Hospital of the MUHC, Montreal General Hospital, Public Health Agency of Canada (PHAC), St. Justine's Hospital, Stollery Children's Hospital, Université de Montréal, University of British Columbia, University of Cincinnati, University of Manitoba, University of Toronto

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary proportion of individuals with IgE mediated allergic reaction The overall objective of this clinical investigation is to estimate the proportion of individuals with IgE mediated allergic reaction to Arepanrix or its components among patients with anaphylaxis/allergic reaction after pH1N1 vaccination, and the proportion that are allergic to the 2010-2011 trivalent inactivated seasonal influenza vaccine (TIV). one year Yes
Secondary Biomarkers that may allow differentiation between ORS and type I hypersensitivity We will try to identify biomarkers that may allow differentiation of patients with ORS and those with type I hypersensitivity to the vaccine. two year Yes
See also
  Status Clinical Trial Phase
Terminated NCT02032056 - Effect of Probiotics in Reducing Infections and Allergies in Young Children During the Complementary Feeding Period N/A
Completed NCT01842711 - Cumulative Irritation Patch Test N/A
Completed NCT01633840 - New Validated Recipes for Double-blind Placebo-controlled Low Dose Food Challenges N/A
Completed NCT00997971 - Growth, Tolerance in Healthy Infants Fed a Partially Hydrolyzed Rice Protein Phase 3
Completed NCT00554983 - Efficacy and Safety From a Recombinant Folding Variant of Bet v 1 Phase 3
Completed NCT00331929 - Respiratory Health Study of Children in Kiryat Tivon N/A
Completed NCT00232518 - Randomised Controlled Clinical Trials of the Effect of Therapeutic Hookworm Infection in Allergic Rhinoconjunctivitis N/A
Completed NCT00220753 - Air Cleaners for Children and Adolescents With Asthma and Dog Allergy N/A
Completed NCT04126096 - Negative Predictive Value and NIC of Beta-Lactam Antibiotics. N/A
Completed NCT04046731 - Neuromuscular Blocking Agents Utilized During Perioperative Hypersensitivity Evaluation N/A
Completed NCT04004351 - Treatment Modalities in Children and Adolescents Suffering From HDM-induced Allergic Rhinitis and/or Asthma
Not yet recruiting NCT05997784 - Study of Indoor Air Pollutants and Their Impact in Childhood Health and Wellbeing
Completed NCT04418999 - Safety and Efficacy of Intracanalicular Dexamethasone Compared to Loteprednol Etabonate in Patients With Keratoconus Early Phase 1
Completed NCT04186949 - Early Origins of Allergy and Asthma
Completed NCT02127801 - Single Ascending-dose Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Participants Phase 1
Enrolling by invitation NCT05011071 - The Alberta BLOOM Premature Child Study
Not yet recruiting NCT06330974 - Allergy, Asthma, and Atopic Eczema in Finland
Completed NCT02596321 - A Study Investigating the Immunologic Effects and Safety of 60-day Treatment of the ALK HDM Tablets in Adult Subjects With HDM-Induced Allergic Rhinitis and/or Atopic Asthma Phase 3
Terminated NCT02601690 - Observational Analysis of T Cell Responses to SPIREs for Multiple Allergens in Subjects With Allergy in North America
Completed NCT02306473 - The Leaky Lung Test Early Phase 1